Skip to content

A Study of TH-SC01 in the Treatment of Radiation-induced Rectal Injury

A Study on the Efficacy and Safety of Endoscopic Local Injection of Umbilical Cord Mesenchymal Stem Cells(TH-SC01) for the Treatment of Radiation-induced Rectal Injury.

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05939778
Enrollment
27
Registered
2023-07-11
Start date
2022-09-21
Completion date
2026-01-21
Last updated
2023-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Injury

Brief summary

The purpose of this study is to evaluate the efficacy and safety of allogeneic umbilical cord mesenchymal stem cells in the treatment of radiation-induced rectal injury.

Detailed description

radiation-induced rectal injury (RRI) is a common clinical disease. The symptoms of RRI often include: Abdominal pain, diarrhea, hematochezia, etc., especially chronic radiation-induced late rectal injury (RLRI), are easy to cause the disease to prolong and not heal. Some patients will have severe complications such as massive rectal bleeding, rectal stenosis, intestinal obstruction, deep ulcer, intestinal perforation, and fistula formation after the disease progresses to the advanced stage, most of which occur 2-5 years after the end of radiotherapy. The incidence of radiation rectal injury is high, which has a serious impact on the health and quality of life of patients. Currently, the commonly used treatment methods include non-steroidal anti-inflammatory drugs, mucosal protective agents, hemostatic agents, compound enema preparations, hyperbaric oxygen, surgical treatment, etc., but there is still no standard treatment strategy and effective plan, and clinical treatment is extremely difficult. Mesenchymal stem cells have the properties of proliferation, differentiation, immune regulation and angiogenesis. There are few clinical studies on the use of mesenchymal stem cells in the treatment of radiation-induced rectal injury. Good therapeutic effect was achieved in vivo and in vitro in the preliminary experiment. The aim of this study was to verify the safety and efficacy of allogeneic mesenchymal stem cells from healthy donors in RRI patients. Primary objective: To assess the safety (incidence of treatment emergent adverse-events) of TH-SC01.

Interventions

BIOLOGICALTH-SC01(Umbilical cord mesenchymal stem cells)

5+7 principle: 1\. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject. 1. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group. 2. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step. 2\. 7 subjects were included in the second step.

Sponsors

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
CollaboratorINDUSTRY
Jinling Hospital, China
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Fully understand and sign the informed consent form; 2. Age ≥18 years and \<80 years; 3. Patients diagnosed with chronic radiation rectal injury after radiation therapy; 4. Patients with LENT-SOMA scale score ≥1; 5. Good physical condition (WHO functional status score 0-1).

Exclusion criteria

1. The patient had severe liver and kidney disease; 2. Severe congestive heart failure or coronary heart disease; 3. Patients have allergic constitutions or severe systemic immune diseases; 4. The patient had active gastrointestinal hemorrhage or acute intestinal obstruction; 5. Patients were pregnant or had other conditions that the investigators deemed unsuitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frameDescription
lentsoma score scale improved > 0.6 points16 weekslentsoma scale can comprehensively reflect the severity of radiation-induced rectal injury from three aspects: subjective feeling, objective situation and intervention measures. There are 14 items in total, each item has a maximum of 4 points, and the final total is divided by 14.

Secondary

MeasureTime frameDescription
The declining level of the Vienna Rectoscopy Score16 weeksThe Vienna Rectoscopy Score evaluated the severity of the disease under colonoscopy in five aspects: the degree of telangiectasia, mucosal congestion, ulceration, stenosis, and necrosis. The most serious score is 5 points.
The decreased level ofSemi-quantitative Score of Rectal Radiological Pathological Injury16 weeksThe histological severity of the rectal injury was assessed by colonoscopy. The most severe rating is 10
The decreased levels of SF-36 Scale16 weeksThe quality of life of patients before and after treatment
The decreasing level of the Rectal Telangiectasia Density Scale(RTD)16 weeksThe degree of capillary dilatation at the lesion site was observed during colonoscopy. There were four grades, with the highest score being 3.
The decreased levels of Visual Analogue Pain Rating Scale16 weeksThe degree of pain is represented by a total of 11 numbers from 0 to 10, 0 means no pain, 10 represents the most pain, according to the degree of pain in the 11 numbers to select a number to represent the pain degree.
Serious adverse event occurred2 yearsCases such as fever, allergy, pain, and severe bleeding should be recorded immediately and treated actively
The decreased levels of Hospital Anxiety and Depression Scales16 weeksTo assess the level of anxiety and depression in the subjects in the hospital

Countries

China

Contacts

Primary ContactFangyu Wang
quanguorenmin1994@163.com0086-13515100636
Backup ContactHaoyu Xu
quanguorenmin1994@163.com0086-17362954983

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026